Gadofosveset

Drugs

Volumn 66, Issue 6, 2006, Pages 851-857

  Henness, Sheridan ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GADOFOSVESET;

BURNING SENSATION; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TOLERABILITY; HEADACHE; HOT FLUSH; HUMAN; HYPERGLYCEMIA; MAGNETIC RESONANCE ANGIOGRAPHY; NAUSEA; PARESTHESIA; PRURITUS; REVIEW; SENSITIVITY AND SPECIFICITY;

ADULT; CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VASCULAR DISEASES;

EID: 33646756230     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666060-00008     Document Type: Review

References (16)

1. European Medicines Agency. Vasovist: scientific discussion [online]. Available from URL: http://www. emea.eu.int/ [Accessed 2006 Jan 25]
2. Lei TH, Udupa JK, Saha PK, et al. 3D MRA visualization and artery-vein separation using blood-pool contrast agent MS-325. Acad Radiol 2002 May; 9 (Suppl. 1): 127-33
3. Caravan P, Amedio JC, Dunham SU, et al. When are two waters worse than one? Doubling the hydration number of a Gd-DTPA derivative decreases relaxivity. Chemistry 2005 Oct 7; 11 (20): 5866-74
4. Caravan P, Cloutier NJ, Greenfield MT, et al. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc 2002 Mar 27; 124 (12): 3152-62
5. Hyslop WB, Balci NC, Semelka RC. Future horizons in MR imaging. Magn Reson Imaging Clin N Am 2005; 13 (2): 211-24
6. Kotek J, Lebduskova P, Hermann P, et al. Lanthanide (III) complexes of novel mixed carboxylic-phosphorus acid derivatives of diethylenetriamine: a step towards more efficient MRI contrast agents. Chemistry 2003 Dec 5; 9 (23): 5899-915
7. Rapp JH, Wolff SD, Quinn SF, et al. Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography - multicenter comparative phase III study. Radiology 2005 Jul; 236 (1): 71-8
8. Grist TM, Korosec FR, Peters DC, et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology 1998 May; 207 (2): 539-44
9. Lauffer RB, Parmelee DJ, Dunham SU, et al. MS-325: albumin-targeted contrast agent for MR angiography. Radiology 1998 May; 207 (2): 529-38
10. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005 Nov; 40 (11): 715-24
11. European Medicines Agency. Vasovist: summary of product characteristics. [online]. Available from URL: http://www.emea.eu.int/ [Accessed 2006 Jan 25]
12. Lauffer RB, Parmelee DJ, Ouellet HS, et al. MS-325: a small-molecule vascular imaging agent for magnetic resonance imaging. Acad Radiol 1996 Aug; 3 Suppl. 2: S356-8
13. Bluemke DA, Stillman AE, Bis KG, et al. Carotid MR angiography: phase II study of safety and efficacy for MS-325. Radiology 2001 Apr; 219 (1): 114-22
14. Perreault P, Edelman MA, Baum RA, et al. MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial. Radiology 2003 Dec; 229 (3): 811-20
15. Goyen M, Edelman M, Perreault P, et al. MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology 2005 Sep; 236 (3): 825-33
16. Schering AG. Gadofosveset prescribing information, Switzerland. February 2006